"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 3 | 2 | 5 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 0 | 5 | 5 |
| 2005 | 1 | 4 | 5 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 3 | 2 | 5 |
| 2010 | 1 | 5 | 6 |
| 2011 | 1 | 4 | 5 |
| 2012 | 0 | 5 | 5 |
| 2013 | 1 | 6 | 7 |
| 2014 | 2 | 13 | 15 |
| 2015 | 7 | 5 | 12 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 5 | 7 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 5 | 6 |
| 2021 | 2 | 4 | 6 |
| 2022 | 1 | 5 | 6 |
| 2023 | 1 | 1 | 2 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
Current Concepts in Molecular Breast Imaging. J Breast Imaging. 2025 Jan 25; 7(1):104-118.
-
Reproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models. PLoS One. 2025; 20(1):e0313123.
-
Radioligand therapies in meningioma: Evidence and future directions. Neuro Oncol. 2024 Dec 09; 26(Supplement_9):S215-S228.
-
Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. Neuro Oncol. 2024 Dec 09; 26(Supplement_9):S208-S214.
-
Whole-Body Multiparametric PET in Clinical Oncology: Current Status, Challenges, and Opportunities. AJR Am J Roentgenol. 2024 Nov; 223(5):e2431712.
-
Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation. Eur J Nucl Med Mol Imaging. 2025 Jan; 52(2):744-755.
-
SNMMI Clinical Trials Network Research Series for Technologists: An Introduction to Conducting Theranostic Clinical Trials. J Nucl Med Technol. 2024 Sep 05; 52(3):184-191.
-
Pitfalls in Positron Emission Tomography/Computed Tomography in the Thorax and Abdomen. Semin Ultrasound CT MR. 2024 Dec; 45(6):488-495.
-
True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024 Jul 01; 65(7):1080-1086.
-
Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial. J Vasc Interv Radiol. 2024 Oct; 35(10):1464-1473.e1.